Development of a 2′,4′-BNA/LNA-based siRNA for Dyslipidemia and Assessment of the Effects of Its Chemical Modifications In Vivo

Recent advances in RNA interference (RNAi)-based drug development have partially allowed systemic administration of these agents in vivo with promising therapeutic effects. However, before chemically modified small-interfering RNAs (siRNAs) can be applied clinically, their in vivo effects should be...

Descripción completa

Detalles Bibliográficos
Autores principales: Wada, Shunsuke, Obika, Satoshi, Shibata, Masa-Aki, Yamamoto, Tsuyoshi, Nakatani, Moeka, Yamaoka, Tetsuji, Torigoe, Hidetaka, Harada-Shiba, Mariko
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group 2012
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3464879/
https://www.ncbi.nlm.nih.gov/pubmed/23344237
http://dx.doi.org/10.1038/mtna.2012.32

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3464879/
https://www.ncbi.nlm.nih.gov/pubmed/23344237
http://dx.doi.org/10.1038/mtna.2012.32

Ejemplares similares